TITLE

Case study: cerebrovascular parkinsonism with levodopa addiction

AUTHOR(S)
Lity, O; Al-Din, A
PUB. DATE
September 2004
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Sep2004, Vol. 75 Issue 9, p1365
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Levodopa, the mainstay of treatment for idiopathic Parkinson's disease, has a mild stimulant effect and may cause agitation, restlessness and euphoria even in normal subjects. It is associated with a well documented withdrawal syndrome consisting of confusion, muscular pain and rigidity. This can progress to involve symptoms comparable with neuroleptic malignant syndrome, including pyrexia and increased creatine kinase. The article focuses on a 81 year old woman had been diagnosed with Parkinson's disease 10 years before.
ACCESSION #
14433362

 

Related Articles

  • DELAYED-ONSET MUSCLE SORENESS IMPROVED BY MASSAGE. Robertshawe, Penny // Journal of the Australian Traditional-Medicine Society;Sep2006, Vol. 12 Issue 3, p151 

    The article presents a study on the use of massage therapy on delayed-onset muscle soreness (DOMS). It identifies the symptoms and occurrence of DOMS. The study included 10 adult subjects with an average age of 23 years, in whom variables were measured. Dependent variables included range of...

  • CK ELEVATIONS EXPLAINED.  // Cortlandt Forum;06/25/2001, Vol. 14 Issue 6, p90 

    Details the asymptomatic elevations of creatine kinase (CK) levels among African American patients. Affirmation on the incidence of benign chronic CK elevations; Observation of myalgia and normal CK specifically in atorvastin; Prevention of myalgias.

  • Neuroleptic malignant-like syndrome with a slight elevation of creatine-kinase levels and respiratory failure in a patient with Parkinson's disease. Li Wei; Yinghui Chen // Patient Preference & Adherence;2014, Vol. 8, p271 

    Neuroleptic malignant-like syndrome (NMLS) is a rare but catastrophic complication of drug treatment for Parkinson's disease (PD). Sudden withdrawal and abrupt reduction of antiparkinsonian drugs are major risk factors. Just as its name suggests, the clinical features of NMLS are similar to...

  • Atorvastatin/simvastatin.  // Reactions Weekly;7/17/2010, Issue 1310, p13 

    The article describes the case of a 49-year-old woman who experienced myalgia and increased creatine kinase levels while receiving atorvastatin and simvastatin for coronary heart disease, hypertension and hyperlipidaemia.

  • New 7:1 diet may offer better odds for Parkinson's patients. Smith, Susan Male // Environmental Nutrition;May94, Vol. 17 Issue 5, p1 

    Discusses the role of diet in management of Parkinson's Disease (PD). Description of PD; L-dopa as standard medication for PD; Protein's effect on medication; 7:1 plan; Elan NutraPharma's Hearty Balance mail-order foods and education program; Other diet concerns; Possibility of prevention of...

  • Treatment of motor complications in advancing Parkinson's disease: Which drugs and when? Ahlskog, J. Eric // Formulary;Aug2000, Vol. 35 Issue 8, p654 

    Discusses treatment of Parkinson's disease patients who experience motor complications, clinical fluctuations and dyskinesias due to levodopa therapy. Addition of a dopamine agonist or entacapone; Adjustment of levodopa therapy with each form of adjunctive therapy; Addition of amantadine in...

  • Five Years' Treatment of Parkinson's Disease with Levadopa. Sweet, Richard D.; McDowell, Fletcher H. // Annals of Internal Medicine;Oct75, Vol. 83 Issue 4, p456 

    Assesses the effects of levodopa treatment in patients with Parkinson's disease. Background of levodopa; Status of Parkinson's disease after five years of levodopa treatment; Correlation of therapeutic results with other factors.

  • Dose-Related Levodopa-Induced Haemolytic Anaemia. Lindstrom, Fole D.; Lieden, Gudrun; Engstrom, Margareta S. // Annals of Internal Medicine;Mar77, Vol. 86 Issue 3, p298 

    Focuses on a study that described a 71 year-old white man which developed direct antiglobulin positive haemolytic anaemia after 16 months of levodopa therapy for Parkinson's disease. History of the patient; Serologic findings; Discussion.

  • Spotlight on rasagiline in Parkinson's disease. Oldfield, Vicki; Keating, Gillian M.; Perry, Caroline M. // CNS Drugs;2008, Vol. 22 Issue 1, p83 

    Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics